SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Eyenovia, Inc. EYEN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Eyenovia, Inc. (EYEN) is a Biotechnology company in the Healthcare sector, currently trading at $7.56. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $813M, +710032.4%/yr average growth. Net income is $47.0B (loss), growing at -31440.7%/yr. Net profit margin is -5777.7% (negative). Gross margin is 62.7% (+62.7 pp trend).

Balance sheet: total debt is $8.5B against $41.1B equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 2.68 (strong liquidity). Debt-to-assets is 16.4%. Total assets: $51.8B.

Analyst outlook: 2 / 7 analysts rate EYEN as buy (29%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 58/100 (Partial), Future 20/100 (Fail), Income 10/100 (Fail).

EYEN SharesGrow Score Overview

43/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 58/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — EYEN

No analyst coverage available for this stock.

EYEN: +710032.4%/yr revenue is, -31440.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet EYEN: Debt-to-Equity (D/E) ratio 0.21 (conservative), Current ratio is 2.68 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

EYEN: Gross margin is 62.7% (+62.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 7 analysts rate EYEN as buy (29%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

EYEN: Net profit margin is -5777.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.85-124.8

Volume29.5K

Avg Volume (30D)4.65M

Market Cap$38.59M

Beta (1Y)1.00

Share Statistics

IPO Date2018-01-25

Employees13

CEOMichael M. Rowe

Financial Highlights & Ratios

Revenue (TTM)$813.46M

Gross Profit$510.17M

EBITDA$-46.72B

Net Income$-47B

Operating Income$-46.72M

Total Cash$6.44B

Total Debt$8.51B

Net Debt$2.07B

Total Assets$51.76B

Price / Sales (P/S)0.05

Analyst Forecast

Rating ConsensusHold

Analysts Covering7

Buy 29% Hold 71% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS30234E2037

Price Chart

EYEN

Eyenovia, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

0.85 52WK RANGE 124.80

People Also View

ImmunityBio, Inc.

Cidara Therapeutics, Inc.

Kodiak Sciences Inc.

Ocular Therapeutix, Inc.

Lexicon Pharmaceuticals, Inc.

Alpha Tau Medical Ltd.

Greenwich LifeSciences, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message